MFA Wealth Services Invests $1.07 Million in Gilead Sciences, Inc. $GILD

Posted by Stanley Muller on Jun 28th, 2026

Gilead Sciences logo MFA Wealth Services acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 7,677 shares of the biopharmaceutical company’s stock, valued at approximately $1,070,000.

A number of other large investors have also recently added to or reduced their stakes in GILD. Trilogy Capital Inc. increased its holdings in Gilead Sciences by 5.2% during the 1st quarter. Trilogy Capital Inc. now owns 31,249 shares of the biopharmaceutical company’s stock valued at $4,355,000 after acquiring an additional 1,546 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in shares of Gilead Sciences by 9.3% in the first quarter. Pictet Asset Management Holding SA now owns 2,574,822 shares of the biopharmaceutical company’s stock valued at $356,943,000 after purchasing an additional 218,308 shares in the last quarter. Traveka Wealth LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $229,000. Union Bancaire Privee UBP SA grew its position in shares of Gilead Sciences by 7.3% in the first quarter. Union Bancaire Privee UBP SA now owns 15,160 shares of the biopharmaceutical company’s stock valued at $2,113,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Sterling Capital Management LLC increased its stake in shares of Gilead Sciences by 25.4% during the 1st quarter. Sterling Capital Management LLC now owns 66,500 shares of the biopharmaceutical company’s stock worth $9,268,000 after purchasing an additional 13,470 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $127.86 on Friday. Gilead Sciences, Inc. has a 1 year low of $106.84 and a 1 year high of $157.29. The company’s 50 day simple moving average is $130.19 and its 200 day simple moving average is $134.28. The company has a market capitalization of $158.75 billion, a price-to-earnings ratio of 17.42 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 44.69%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Truist Financial restated a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Daiwa Securities Group dropped their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Morgan Stanley reduced their price objective on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Finally, Jefferies Financial Group began coverage on Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.41.

Check Out Our Latest Report on GILD

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 68,000 shares of company stock worth $8,930,150. 0.30% of the stock is currently owned by insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Trodelvy won first-line approval in the U.S. and Europe for metastatic triple-negative breast cancer, opening a larger treatment market and improving Gilead’s oncology growth profile. Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $155 price target after positive HIV trial results, signaling continued analyst confidence in Gilead’s pipeline and longer-term earnings potential. Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
Positive Sentiment: Merck’s FDA announcement that KEYTRUDA combinations can be used with Trodelvy in first-line advanced TNBC adds another validation point for Trodelvy’s role in frontline cancer care. FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as First-Line Treatment of Advanced Triple-Negative Breast Cancer
Neutral Sentiment: Recent coverage also noted Gilead’s stock had been drifting lower before the approval news, reflecting recent market weakness rather than a change in fundamentals. Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.